These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28825515)

  • 1. Safety and effectiveness assessment of 2011-2012 seasonal influenza vaccine produced in China: a randomized trial.
    Jing-Xia G; Yu-Liang Z; Jin-Feng L; Shu-Zhen L; Guo-Yang L; Qi L
    Postgrad Med; 2017 Nov; 129(8):907-914. PubMed ID: 28825515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
    Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
    DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
    Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.
    Liang XF; Wang HQ; Wang JZ; Fang HH; Wu J; Zhu FC; Li RC; Xia SL; Zhao YL; Li FJ; Yan SH; Yin WD; An K; Feng DJ; Cui XL; Qi FC; Ju CJ; Zhang YH; Guo ZJ; Chen PY; Chen Z; Yan KM; Wang Y
    Lancet; 2010 Jan; 375(9708):56-66. PubMed ID: 20018364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, controlled, blinded study of the safety, immunogenicity and batch consistency of Aleph inactivated split influenza vaccine made in China in Chinese people.
    Li S; Li L; Ai X; Yang L; Bai Y; Wang Z; Han H; Lu Q; Luo F; Zhang Z; Liu C; Xiao J; Shi N
    Hum Vaccin Immunother; 2014; 10(3):557-65. PubMed ID: 24301228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China.
    Wang SY; Liu SZ; Chu K; Zhao Y; Zhu FC; Hu YM; Meng FY; Li JX; Luo L; Yang JY; Liu P; Yu J
    Expert Rev Vaccines; 2017 Nov; 16(11):1155-1169. PubMed ID: 28870140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China.
    Mo Z; Nong Y; Liu S; Shao M; Liao X; Go K; Lavis N
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-7. PubMed ID: 28301266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of 3 seasonal trivalent influenza vaccines in the Chinese military.
    Gao D; Yang H; Deng B; Yin G; Song W; Zhang H; Li Y
    Hum Vaccin Immunother; 2016 Oct; 12(10):2634-2639. PubMed ID: 27348250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial.
    McKittrick N; Frank I; Jacobson JM; White CJ; Kim D; Kappes R; DiGiorgio C; Kenney T; Boyer J; Tebas P
    Ann Intern Med; 2013 Jan; 158(1):19-26. PubMed ID: 23277897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
    Vesikari T; Block SL; Guerra F; Lattanzi M; Holmes S; Izu A; Gaitatzis N; Hilbert AK; Groth N
    Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a Trivalent Influenza HA vaccine in Indonesian infants and children.
    Soedjatmiko S; Medise BE; Gunardi H; Sekartini R; Satari HI; Hadinegoro SR; Bachtiar NS; Sari RM
    Vaccine; 2018 Apr; 36(16):2126-2132. PubMed ID: 29551225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial.
    McAllister L; Anderson J; Werth K; Cho I; Copeland K; Le Cam Bouveret N; Plant D; Mendelman PM; Cobb DK
    Lancet; 2014 Aug; 384(9944):674-81. PubMed ID: 24881803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
    Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P; Ince D; Noah DL; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1409-19. PubMed ID: 25291577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.
    Nolan T; McVernon J; Skeljo M; Richmond P; Wadia U; Lambert S; Nissen M; Marshall H; Booy R; Heron L; Hartel G; Lai M; Basser R; Gittleson C; Greenberg M
    JAMA; 2010 Jan; 303(1):37-46. PubMed ID: 20026597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to a monovalent 2009 influenza A (H1N1) vaccine.
    Greenberg ME; Lai MH; Hartel GF; Wichems CH; Gittleson C; Bennet J; Dawson G; Hu W; Leggio C; Washington D; Basser RL
    N Engl J Med; 2009 Dec; 361(25):2405-13. PubMed ID: 19745216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.
    Frey SE; Bernstein DI; Brady RC; Keitel WA; El Sahly H; Rouphael NG; Mulligan MJ; Atmar RL; Edupuganti S; Patel SM; Dickey M; Graham I; Anderson EL; Noah DL; Hill H; Wolff M; Belshe RB
    Vaccine; 2015 Jan; 33(1):163-73. PubMed ID: 25444805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.